Phase II Single Arm, Open Label, Single Institution Study of Continuous Sunitinib (Sutent) in Patients With High-Risk (BCG-Refractory) Superficial Transitional Cell Carcinoma (TCC) of the Bladder
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2015 Planned End Date changed from 1 Jul 2012 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
- 05 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.